Trial Profile

A phase I trial of House-dust-mite-allergy-immunotherapy-ALK-Abello

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Feb 2023 According to an ALK-Abello media release, Biologics License Application (BLA) for house dust mite (HDM) sublingual allergy immunotherapy (AIT) tablet has been accepted for review by the National Medical Products Administration (NMPA) in China. The BLA, for treatment of persistent moderate-to-severe HDM allergic rhinitis in patients aged 12-65 was submitted in late December 2022.
10 Mar 2022 New trial record
03 Mar 2022 According to an ALK-Abello media release, in preparation for BLA application, ALK has completed this Phase I trial in China and had initiated a Phase III, local registration trial in adult allergic rhinitis. However, the Phase III trial has been paused since 2020 as a consequence of the COVID pandemic.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com